Empaveli is a Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Apellis Pharmaceuticals, Inc.. The primary component is Pegcetacoplan.
Product ID | 73606-010_bbd711fa-c1f0-458c-b916-230ac774f8dd |
NDC | 73606-010 |
Product Type | Human Prescription Drug |
Proprietary Name | Empaveli |
Generic Name | Pegcetacoplan |
Dosage Form | Injection, Solution |
Route of Administration | SUBCUTANEOUS |
Marketing Start Date | 2021-05-14 |
Marketing Category | NDA / |
Application Number | NDA215014 |
Labeler Name | Apellis Pharmaceuticals, Inc. |
Substance Name | PEGCETACOPLAN |
Active Ingredient Strength | 1080 mg/20mL |
Pharm Classes | Complement Inhibitor [EPC],Complement Inhibitors [MoA] |
NDC Exclude Flag | N |
Listing Certified Through | 2022-12-31 |
Marketing Start Date | 2021-05-14 |
NDC Exclude Flag | N |
Sample Package? | N |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
EMPAVELI 97460836 not registered Live/Pending |
Apellis Pharmaceuticals, Inc. 2022-06-15 |
EMPAVELI 90505492 not registered Live/Pending |
Apellis Pharmaceuticals, Inc. 2021-02-02 |